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The supply of transfusable red blood cells (RBCs) is not suﬃcient in many countries. If transfusable RBCs could be produced
abundantly from certain resources, it would be very useful. Our group has developed a method to produce enucleated RBCs
eﬃcientlyfromhematopoieticstem/progenitorcellspresentinumbilicalcordblood.Morerecently,itwasreportedthatenucleated
RBCs could be abundantly produced from human embryonic stem (ES) cells. The common obstacle for application of these
methods is that they require very high cost to produce suﬃcient number of RBCs that are applicable in the clinic. If erythroid
cell lines (immortalized cell lines) able to produce transfusable RBCs ex vivo were established, they would be valuable resources.
Our group developed a robust method to obtain immortalized erythroid cell lines able to produce mature RBCs. To the best of
our knowledge, this was the ﬁrst paper to show the feasibility of establishing immortalized erythroid progenitor cell lines able to
produce enucleated RBCs ex vivo. This result strongly suggests that immortalized human erythroid progenitor cell lines able to
produce mature RBCs ex vivo can also be established.
1.Introduction
Transfusion therapies involving RBCs, platelets, and neu-
trophils depend on the donation of these cells from healthy
volunteers. However, unpredictable adverse results can ensue
from transfusion therapies because of the donation of
cells from a very large number of anonymous volunteers.
For example, transfusion of blood products that include
hazardous viruses or prions is diﬃcult to prevent completely,
because, occasionally, tests to detect them yield pseudo-
negativeresults.ThereislittledoubtthatRBCs,platelets,and
neutrophilsproducedexvivowouldbecandidatematerialsto
replace cells donated from such a large group of anonymous
individuals.
The development of technologies such as PCR and gene
knockout that enable the manipulation of an organism’s
genetic material contributed tremendously to progress in
the life sciences in the ﬁnal decades of the last century.
This century looks to continue this progress through the
development of further new technologies relating to cell
manipulation.
2. Discovery of Plasticityin Terminally
Differentiated Cells
It was believed for a long time that epigenetic modiﬁcations
in diﬀerentiated somatic cells were irreversible. This meant
that terminally diﬀerentiated cells could never return to
being immature cells. However, in 1962, it was reported
that the nuclei of somatic cells of an amphibian (frog) were
reprogrammed following transfer into enucleated unfertil-
ized eggs [1]. Following transfer of a somatic cell nucleus,
the egg could undergo cell division and diﬀerentiate to
produce an adult frog. This result clearly indicated that
epigenetic modiﬁcations in terminally diﬀerentiated somatic
cells were reversible. Dr. John Gurdon, who performed
this groundbreaking study, received the Albert Lasker Basic
Medical Research Award in 2009.
Initially, many biologists believed that this reversibility
of epigenetic modiﬁcations in terminally diﬀerentiated cells
was restricted to amphibian somatic cells and did not occur
in mammalian somatic cells. However, in 1997, a nuclear
transfer experiment in sheep in which somatic nuclei were2 Stem Cells International
transferred into unfertilized eggs showed that epigenetic
modiﬁcations in terminally diﬀerentiated mammalian
somatic cells were also reversible [2]. This experiment
famously resulted in the birth of the ﬁrst live cloned sheep,
named “Dolly”.
3.Immortalization of ESCells
The methodology for isolating and culturing mouse ES cells
was ﬁrst developed in 1981 [3] and has aided research in
a wide range of biological studies. Dr. Martin Evans, who
developed the technology for establishing mouse ES cell
lines, was awarded a Nobel Prize in 2007 together with Dr.
Mario Capecchi and Dr. Oliver Smithies, who developed
homologous recombination technology in mouse ES cells.
As a result of these technical advances, functional analysis
of genes has progressed considerably using mice with gene
knockouts or other genetic modiﬁcations.
It is well known that mouse cells can be immortalized
simply by continuous in vitro culture, for example, using the
so-called“3T3protocol”.Onewidelyexploitedexampleofan
immortalizedcelllineisNIH3T3,whichcontinuestobeused
in a wide range of experiments. In contrast, it is not possible
to immortalize human somatic cells in a similar manner and
this diﬃculty gave rise to the widespread assumption that
it would not be possible to establish human ES cell lines.
However, in 1998, 17 years after the ﬁrst establishment of
mouse ES cell lines, it was reported that human ES cell lines
could also be produced by continuous in vitro culture [4].
4. Therapeutic Cloning
The ability to reprogram mammalian somatic cells by
nuclear transfer and to establish human ES cell lines stim-
ulated medical scientists to investigate the creation of ES cell
lines using nuclear transfer as a potential means of achieving
“therapeutic cloning”. If this technology could be established
as a viable therapy, then patients who would beneﬁt from
somatic cell transplantation could be treated with nuclear-
transferred ES cells produced using their own somatic cells,
which would avoid the possibility of transplant rejection as
the cells possess the same major histocompatibility (MHC)
antigens as host tissue.
Although an earlier report of successful therapeutic
cloning by a group in Korea proved false, it was recently
reported that primate ES cell lines have been established by
n u c l e a rt r a n s f e rt e c h n o l o g y[ 5]. Since unfertilized primate
eggs are much more fragile than those of rodents, it may
still take some time to establish the technology for use in
human therapeutic cloning. However, the prospect of using
such therapy no longer seems to be so distant.
5.ASearchforAlternativeTechnologiesto
Therapeutic Cloning
An important limitation to the use of therapeutic cloning
is that it requires unfertilized eggs. Human eggs are very
diﬃcult to obtain, and, moreover, their use for this purpose
also raises serious ethical issues. For these reasons, a search
has been initiated for alternative methodologies that avoid
n u c l e a rt r a n s f e r .O n ea p p r o a c hh a sb e e nt os e a r c hf o rf a c t o r s
in unfertilized eggs that may be required for the repro-
gramming of transferred somatic nuclei. Another avenue
of research has been to elucidate which genes speciﬁcally
function in ES cells, since these genes may maintain the
undiﬀerentiated state of ES cells, and thus might be able to
induce reprogramming of nuclei in terminally diﬀerentiated
somatic cells.
The research group led by Dr. Shinya Yamanaka reported
the ﬁrst success in the latter approach. They were able
to induce diﬀerentiated mouse somatic cells to become
pluripotent stem cells by the application of four deﬁned
factors [6]. The enforced expression of the transcription
factors Oct3/4, Sox2, Klf4, and c-Myc in terminally diﬀer-
entiated somatic cells induced cellular reprogramming and
changed the cells into ES-like pluripotent stem cells. These
reprogrammed cells were named “induced pluripotent stem
(iPS) cells”. Subsequently, in the year after establishment of
human iPS cell lines was ﬁrst reported, several other groups
also succeeded with this methodology [7–10]. Dr. Shinya
Yamanaka, who developed the method, was given the Albert
Lasker Basic Medical Research Award in 2009 together with
Dr. John Gurdon.
The mechanisms underlying the reprogramming of
terminally diﬀerentiated somatic cells following the enforced
expression of the four factors remain to be elucidated. It is
now known that expression of these factors after exogenous
introduction is completely suppressed in established iPS
cells.Thus,thefactorsseemtoberequiredonlyfortherepro-
gramming process but not for maintenance of pluripotency.
Regardless of the mechanisms involved, this discovery clearly
indicated that terminally diﬀerentiated somatic cells could
be reprogrammed without nuclear transfer into unfertilized
eggs and opened a new dawn for therapeutic cloning [11–
13].
6.Ex Vivo RBC Production from
Hematopoietic Stem/Progenitor Cells
The rapid progress relating to cell manipulation technology
described above prompted many scientists in various ﬁelds
to consider cell therapy using the cells produced and/or
manipulated ex vivo. The scientists in the ﬁeld of hematology
are naturally aiming to produce the terminally diﬀerentiated
blood cells able to use in the clinic. RBC transfusion was
the ﬁrst transplantation procedure to be established and is
now routine and indispensable for many clinical purposes.
However, in many countries, the supply of transfusable
materials is not always suﬃcient. In Japan, for example, the
supply of RBCs with an AB/RhD(−) phenotype is always
lacking, because individuals with this RBC phenotype are
rare. This problem of inequalities in the supply and demand
for RBCs has stimulated interest in the development of ex
vivo procedures for the generation of functional RBCs from
hematopoietic stem cells or progenitor cells.
The hematopoietic stem cells that are present in bone
marrow and umbilical cord blood are promising materialsStem Cells International 3
for ex vivo production of RBCs. In particular, umbilical cord
blood cells are readily available, as they are usually discarded.
Provided the mother of a neonate consents to use of the
umbilical cord, this material can provide a useful resource
without any further complicating critical or ethical concerns.
Neildez-Nguyen et al. reported that human erythroid
cells (nucleated cells) produced on a large scale ex vivo
could diﬀerentiate in vivo into enucleated RBCs [14]. They
developed a culture protocol to expand CD34+ erythroid
progenitor cells based on a 3-step expansion of cells by
sequential supply of speciﬁc combinations of cytokines to
the culture medium [14]. This study demonstrated that ery-
throid progenitor cells produced ex vivo from hematopoietic
stem and/or progenitor cells could have a clinical application
as an alternative method for transfusing terminally diﬀer-
entiated RBCs. Later, the same group described an ex vivo
methodology for producing fully mature human RBCs from
hematopoietic stem/progenitor cells [15]. The enucleated
RBCs produced by this approach are potentially even more
valuable, as they should be functional immediately after
transfusion without requiring time for enucleation as is
necessary with the erythroid cells.
7. Enucleationof ErythroidProgenitor Cells
The mechanism of erythroblast enucleation, a critical step
in RBC production, has not yet been fully elucidated
[16, 17]. The role of the interaction of erythroblasts with
other cells, such as macrophages, is a controversial topic in
this process [18–22]. Macrophages in retinoblastoma gene-
(Rb-) deﬁcient embryos are unable to physically interact
with erythroblasts, and RBC production is impaired in
these embryos [21]. In addition, in vitro production of
enucleated RBCs from immature hematopoietic progenitor
cells proceeds eﬃciently in the presence [15] but not in the
absence [14] of feeder cells.
However, enucleation can apparently be initiated ex vivo
in erythroblasts that have been induced to diﬀerentiate in
vivo to a developmental stage that is competent for nuclear
self-extrusion [22, 23]. Consistent with these ﬁndings, our
group discovered a method to produce enucleated RBCs
eﬃciently ex vivo without use of feeder cells [24]. Our
systemforexpandingerythroidprogenitorcellsandinducing
eﬃcient enucleation of those progenitor cells is shown in
Figure 1.
The method we developed included VEGF and IGF-
II in the culture medium [24]. These two factors have
been reported to promote the survival, proliferation, and/or
diﬀerentiation of hematopoietic progenitors [25–27]. Con-
sistentwiththeseﬁndings,thesefactorspromotedtheexpan-
sion of erythroid progenitors [24]. However, a much more
important feature of our culture system is that it allowed
erythroid cells to diﬀerentiate to a developmental stage
competent for nuclear self-extrusion [24]. It has generally
been thought that eﬃcient enucleation of erythroblasts is
largely dependent on signals mediated by cells in their
local environment [18–21]. However, the data we reported
demonstrate that the interaction of erythroblasts with other
cells is not necessary for eﬃcient erythroblast enucleation
Hematopoietic stem/progenitor cells
Passage I (6days): SCF, EPO, IL-3, VEGF and IGF-II
Passage II (4days): SCF and EPO
Passage III (6days): SCF and EPO
Passage IV (4days): MAP and mifepristone
Enucleated red blood cells
Figure 1: Culture protocol for the eﬃcient production of enu-
cleated red blood cells without feeder cells from hematopoietic
stem/progenitor cells. Passage I∼III are the steps to expand ery-
throid progenitor cells. Passage IV is the step to induce enucleation
of progenitor cells. SCF, stem cell factor; EPO, erythropoietin; IL-
3, interleukin-3. VEGF, vascular endothelial growth factor; IGF-
II, insulin-like growth factor-II; MAP, mixture of D-mannitol,
adenine, and disodium hydrogen phosphate dodecahydrate.
[24]. Signals mediated by humoral factors appear to be
suﬃcient for the eﬃcient autonomous completion of ery-
throblast enucleation. In addition, since culture without the
use of feeder cells is technically easier and less expensive, the
method we developed has the potential to be a cost-eﬀective
means of producing transfusable RBCs on a large scale from
immature hematopoietic stem/progenitor cells.
8. RBC Productionfrom ES/iPSCells
ES/iPS cells possess the potential to produce various diﬀer-
entiated cells able to function in vivo, and thus represent
another promising resource for RBC production ex vivo.
Furthermore, since ES/iPS cell lines are immortalized, they
can be used repeatedly and have potential to produce abun-
dant diﬀerentiated cells in the quantities required for clinical
use. However, it will be important to carry out routing
screening of the ES/iPS cell lines for de novo chromosomal
aberrations and/or genetic mutations that may arise during
culture, before these long-term cell cultures are applied in
the clinic. Unsurprisingly, there is now a widespread and
enthusiastic debate on standardization of the characteristics
of ES/iPS cells for regenerative medicine protocols that
exploit these cell lines. In our opinion, since chromosomal
aberrations and genetic mutations are inevitable in long-
term cell cultures, only ES/iPS cell lines that have been
cultured for a limited period, for example, less than 30
passages, should be selected for clinical use.
Hematopoietic cells, including those in the erythroid
lineage, have been generated from mouse ES cells [28–31],
nonhuman primate ES cells [32–34], and human ES cells
[35–41]. Our group has also established a long term in vitro
method for culturing hematopoietic cells derived from ES
cells of the nonhuman primate, the cynomolgus monkey
[27]. Recently, abundant productions of mature RBCs from
human ES cells [42]a n dh u m a ni P Sc e l l s[ 43] were also
reported.4 Stem Cells International
9. Establishment of Immortalized
ErythroidProgenitorCellLinesAble to
Produce Enucleated RBCs
As described above, we can now produce mature RBCs
by in vitro culture of ES/iPS cells or the hematopoietic
stem/progenitor cells present in umbilical cord blood. In
practice, however, the eﬃciency of RBC generation varies
with the quality of the ES/iPS cell line, or the umbilical
cord blood sample. Since ES/iPS cell lines can be utilized
repeatedly, derivation of RBCs from ES/iPS cells appears to
be more practical. However, even with optimal experimental
procedures and the most appropriate ES/iPS cell line the
generation of abundant RBCs directly from ES/iPS cells is a
costly and time-consuming process. If immortalized human
erythroid progenitor cell lines can be established that have
eﬃcient production of mature RBCs, they would provide a
much more useful resource than ES/iPS cell lines.
Several mouse and human erythroid cell lines have been
established. However, to the best of our knowledge, there is
no cell line that can eﬃciently diﬀerentiate into enucleated
RBCs. It is generally diﬃcult to establish hematopoietic cell
lines from adult hematopoietic stem and progenitor cells,
as both are sensitive to DNA damage and are unable to
maintain the lengths of telomere repeats on serial passage
[43]. In contrast, ES cells are relatively resistant to DNA
damage and maintain telomere lengths on serial passage
[44]. Therefore, these characteristics of ES/iPS cells may
be advantageous for the establishment of cell lines, since
diﬀerentiatedcellsderivedfromES/iPScellsmayretainthem.
In fact, an erythroid cell line has been established from in
vitro-diﬀerentiated GATA-1-deﬁcient mouse ES cells [45].
Recently, we developed a robust method to obtain diﬀer-
entiated cell lines following the induction of hematopoietic
diﬀerentiation of mouse ES cells (Figure 2) and established
ﬁve independent hematopoietic cell lines using this method
[46]. Three of these lines exhibited characteristics of ery-
throid cells, and they were designated mouse ESc e l l - derived
erythroid progenitor (MEDEP) cell lines. Although their
precise characteristics varied, each of the MEDEP lines
could diﬀerentiate in vitro into more mature erythroid cells,
including enucleated RBCs. Following transplantation into
mice suﬀering from acute anemia, MEDEP cells proliferated
transiently and subsequently diﬀerentiated into functional
RBCs. Treated mice showed a signiﬁcant amelioration of
acuteanemia.Inaddition,MEDEPcellsdidnotformtumors
following transplantation into mice. This paper was the ﬁrst
to demonstrate the feasibility of establishing immortalized
erythroid cell lines able to produce mature RBCs.
After the work above, we have continuously cultured
the established MEDEP cell lines so as to observe whether
the characteristics of them were stable. After long-term
cultures for more than one and a half year, all MEDEP cell
lines maintained the characteristics able to diﬀerentiate into
mature erythroid cells producing hemoglobin abundantly
(Figure 3). Of note, the characteristics of one of the MEDEP
cell lines, MEDEP-BRC5, have changed to that able to
produce enucleated RBCs very eﬃciently; that is, more
Embryonic stem cells
Phase I: Feeder cells (OP9), VEGF and IGF-II
culture for 4days
Phase II: Feeder cells (OP9), SCF, EPO, IL-3 and dexamethasone
culture for approximately 2months
Phase III: SCF, EPO, IL-3 and dexamethasone
culture in the absence of feeder cells
Phase IV: Essential factor(s) alone
culture for maintenance
Figure 2: Culture protocol to establish erythroid progenitor cell
lines from embryonic stem cells. In most cases, the cells failed to
proliferate within two months of the initial induction of diﬀerentia-
tion from ES cells. Induced cells that could proliferate continuously
forapproximatelytwomonths(60days)weresubsequentlycultured
in the absence of OP9 cells and in the presence of hematopoietic
humoral factors. Cells that could proliferate in the absence of
OP9 cells were cultured further. Approximately four months after
the initial induction of diﬀerentiation of the cells, we evaluated
the factors that were essential for the proliferation of each cell
line. VEGF, vascular endothelial growth factor; IGF-II, insulin-like
growth factor-II; SCF, stem cell factor; EPO, erythropoietin; IL-3,
interleukin-3.
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Figure 3: In vitro diﬀerentiation of a MEDEP cell line, MEDEP-
BRC5. MEDEP-BRC5 cells cultured continuously for more than
one and a half year was analyzed. The in vitro diﬀerentiation
of MEDEP-BRC5 was performed by culture for four days after
deprivation of stem cell factor and addition of erythropoietin. (a)
Cell pellets before and after in vitro diﬀerentiation. Red cell pellet
indicates abundant hemoglobin production in the cells. (b) Flow
cytometric analyses. Before and After, the cells before and after
in vitro diﬀerentiation; CD71, transferrin receptor; TER119, a cell
surface antigen speciﬁc for mature erythroid cells.Stem Cells International 5
B
e
f
o
r
e
A
f
t
e
r
85.4%
69.4%
Propidium iodide
Propidium iodide
C
e
l
l
c
o
u
n
t
C
e
l
l
c
o
u
n
t
Forward scatter
Forward scatter
S
i
d
e
s
c
a
t
t
e
r
S
i
d
e
s
c
a
t
t
e
r
100
101
102
103
104
100
101
102
103
104
100
101
102
103
104
100
101
102
103
104
T
E
R
1
1
9
T
E
R
1
1
9
0
50
100
150
200
250
0
100
200
300
0 200 400 600 800 1000
0 200 400 600 800 1000
100 101 102 103 104
100 101 102 103 104
100 101 102 103 104
100 101 102 103 104
a
b c
SYTO16
SYTO16
(A)
a b c
(B)
Figure 4:In vitro enucleationofaMEDEPcellline,MEDEP-BRC5.TheinvitrodiﬀerentiationofMEDEP-BRC5wasperformedasdescribed
in Figure 3. (A) Flow cytometric analyses. Before and After, the cells before and after in vitro diﬀerentiation. Percentages of propidium
iodide-negative viable cells are shown. TER119, see Figure 3. SYTO16, a cell membrane-permeable ﬂuorochrome dye to stain nucleic acids.
Following in vitro diﬀerentiation, 52% of the cells were TER119-positive and SYTO16-negative cells, that is, the cells lacking nuclei. (B)
Morphology of cells collected from the a, b, and c fractions shown in (A). Scale bars indicate 20µm.
than 50% of the cells were the enucleated RBCs following
the induction of diﬀerentiation into mature erythroid cells
(Figure 4). This result demonstrates that the interaction of
erythroid progenitor cells with other cells is not necessary
for eﬃcient enucleation.
At present, the mechanism underlying the establishment
of diﬀerentiated cell lines from ES cells has not been elu-
cidated. Nevertheless, the data we reported clearly indicate
that useful erythroid cell lines can be reproducibly obtained
from mouse ES cells. Given that diﬀerentiation strategies
developed for mouse ES cells often diﬀer from those applied
to human ES cells [47], the method we developed [46]m a y
not be directly applicable to human ES cells and will require
some modiﬁcation.
10. iPSCells asa Source for
Establishing ImmortalizedErythroid
Progenitor Cell Lines
To establish the MEDEP cell lines, we screened eight types
of mouse ES cell line and succeeded in establishing MEDEP
cell lines from three of these [46]. By extrapolation from
this result, it may be that many more human ES cell
lines than currently available worldwide will be necessary
to establish usable erythroid cell lines. In this context, the
establishment of human iPS cell lines [7–10] should help
to solve the problem of a potential shortfall, since human
iPS cells have very similar characteristics as human ES
cells.6 Stem Cells International
Therefore, we attempted to establish human iPS cell
lines and were able to establish a number of human iPS
cell lines using ﬁbroblast-like cells derived from neonatal
tissues [48]. Fortunately, we were able to induce abundant
numbers of hematopoietic cells from some of these iPS cell
lines and also to establish immortalized hematopoietic cell
lines from the induced hematopoietic cells (unpublished
results). Currently, we are investigating the characteristics of
these immortalized hematopoietic cell lines. Some seem to
be erythroid cell lines.
11. ClinicalApplication of Erythroid
Progenitor CellLines
We reported that MEDEP cells did not exhibit tumorigenic-
ity in vivo [46]. Nevertheless, the tumorigenic potential of
any human erythroid cell line will need to be thoroughly
analyzed prior to clinical use [49, 50]. In addition, it may
be advisable to engineer these cells in such a way that they
are eliminated if a malignant phenotype arises for any reason
[51].
Alternatively, the use of terminally diﬀerentiated cells
that no longer have the capability of proliferating should
allow clinical applications of ES/iPS cell derivatives without
the associated risk of tumorigenicity. Thus, for example,
RBCs lack nuclei following terminal diﬀerentiation and are
highly unlikely to exhibit tumorigenicity in vivo.A ss u c h ,
even if the original ES/iPS cells and/or their derivatives
possessed abnormal karyotypes and/or genetic mutations,
they might, nonetheless, be useful for clinical applications,
provided that they can produce enucleated RBCs. Indeed,
the MEDEP lines included many cells possessing abnormal
karyotypes;however,thevastmajority ofthecellsineachcell
line, nevertheless, diﬀerentiated into mature erythroid cells
and transplantation of these cells signiﬁcantly ameliorated
anemia [46].
As described in this paper, various methods have been
developed that enable the ex vivo production of enucleated
RBCs from human hematopoietic stem/progenitor cells [14,
15, 24] and ES/iPS cells [42, 43]. Therefore, once appropriate
erythroid progenitor cell lines have been established, it
should be possible to apply these methods for producing
enucleated RBCs ex vivo. Since RBCs are much smaller than
normal nucleated cells, RBCs produced ex vivo could be
selected by size prior to use in the clinic so as to exclude
nucleated cells, for example, by ﬁltration. In addition, X-ray
irradiation might be useful for eradicating any contaminat-
ing nucleated cells without aﬀecting the RBCs.
Another potential obstacle to the clinical use of ES/iPS
cell derivatives is that of immunogenicity [52, 53]. Trans-
planted MEDEP cells could not ameliorate acute anemia
in mouse strains other than those from which each indi-
vidual cell line was derived or in immunodeﬁcient mice
[46], suggesting immunological rejection in heterologous
strains. Hence, the clinical application of erythroid cell lines
will require use of many cell lines that express diﬀerent
majorhistocompatibility (MHC)antigens.However,exvivo-
generated RBCs need to be compatible with ABO and
RhD antigens alone. Furthermore, the establishment of an
immortalized human erythroid cell line lacking the genes
to produce A, B, and RhD antigens would be a very
useful resource for clinical application, since such a cell line
would produce O/RhD(−) RBCs, which would, in theory, be
transfusable into all individuals.
12. Conclusions
It is now highly likely that immortalized human erythroid
progenitor cell lines able to produce enucleated RBCs can be
establishedinthenearfuture.Webelievethatthetransfusion
of RBCs produced ex vivo from such cell lines will become a
standard procedure in the clinic.
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